MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581635 | Name: Argipressin, des-glynh2(9)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Argipressin, des-glynh2(9)-, can effect on aggregation of blood platelets.

Chemical Structure

Argipressin, des-glynh2(9)-
CAS#37552-33-3

Theoretical Analysis

MedKoo Cat#: 581635

Name: Argipressin, des-glynh2(9)-

CAS#: 37552-33-3

Chemical Formula: C44H61N13O12S2

Exact Mass: 1027.4004

Molecular Weight: 1028.17

Elemental Analysis: C, 51.40; H, 5.98; N, 17.71; O, 18.67; S, 6.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Argipressin, des-glynh2(9)-; DEAVP; DGAVP; 9-Des-glynh2-argipressin; 9-Deglycinamide-argipressin; (Arg8,de-Gly9)-vasopressin.
IUPAC/Chemical Name
((4S,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-D-prolyl-L-arginine
InChi Key
SXYIOPJBWYQZRQ-XJVLYCIZSA-N
InChi Code
InChI=1S/C44H61N13O12S2/c45-26-21-70-71-22-32(42(67)57-17-5-9-33(57)41(66)52-28(43(68)69)8-4-16-50-44(48)49)56-40(65)31(20-35(47)60)55-37(62)27(14-15-34(46)59)51-38(63)30(18-23-6-2-1-3-7-23)54-39(64)29(53-36(26)61)19-24-10-12-25(58)13-11-24/h1-3,6-7,10-13,26-33,58H,4-5,8-9,14-22,45H2,(H2,46,59)(H2,47,60)(H,51,63)(H,52,66)(H,53,61)(H,54,64)(H,55,62)(H,56,65)(H,68,69)(H4,48,49,50)/t26-,27-,28-,29-,30-,31-,32+,33+/m0/s1
SMILES Code
C1[C@@H](NC([C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC([C@@H](NC(=O)[C@H](CSS1)N)Cc1ccc(cc1)O)=O)Cc1ccccc1)CCC(N)=O)CC(N)=O)=O)C(N1[C@@H](C(N[C@@H](CCCNC(N)=N)C(=O)O)=O)CCC1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,028.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Golubeva MG. [Functional activity of vasopressin analog desglycinamide-arginine-vasopressin]. Izv Akad Nauk Ser Biol. 2006 May-Jun;(3):297-305. Review. Russian. PubMed PMID: 16771143. 2: Golubeva MG, Grigoreva ME, Smirnova MP. Correction of changes in ADP-induced platelet aggregation with vasopressin analogue desglycinamide-arginine-vasopressin. Bull Exp Biol Med. 2005 Aug;140(2):162-4. PubMed PMID: 16282990. 3: Reijmers LG, Hoekstra K, Burbach JP, van Ree JM, Spruijt BM. Long-term impairment of social memory in the rat after social defeat is not restored by desglycinamide-vasopressin. Neurosci Lett. 2001 Jun 15;305(3):145-8. PubMed PMID: 11403926. 4: Lança AJ, Wu PH, Jung B, Liu JF, Ng V, Kalant H. Differential increase in Fos immunoreactivity in hypothalamic and septal nuclei by arginine8-vasopressin and desglycinamide9-arginine8-vasopressin. Neuroscience. 1999;91(4):1331-41. PubMed PMID: 10391440. 5: Vawter MP, De Wied D, Van Ree JM. Vasopressin fragment, AVP-(4-8), improves long-term and short-term memory in the hole board search task. Neuropeptides. 1997 Oct;31(5):489-94. PubMed PMID: 9413027. 6: Golubeva MG, Kalishevskaia TM, Grigor'eva ME. [Modeling disorders of platelet hemostasis and correction of them with an analog of vasopressin DGAVP]. Dokl Akad Nauk. 1996 May;348(2):270-1. Russian. PubMed PMID: 8924859. 7: Kudriashov IE, Ivanova EM. [The mechanisms of the effect of a vasopressin analog on the efficiency of glutamatergic transmission in the hippocampus]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1995 May-Jun;45(3):589-92. Russian. PubMed PMID: 7645336. 8: Bruins J, Hijman R, Van Ree JM. Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers. Peptides. 1995;16(2):179-86. PubMed PMID: 7784246. 9: Craane-van Hinsberg WH, Bax L, Flinterman NH, Verhoef J, Junginger HE, Boddé HE. Iontophoresis of a model peptide across human skin in vitro: effects of iontophoresis protocol, pH, and ionic strength on peptide flux and skin impedance. Pharm Res. 1994 Sep;11(9):1296-300. PubMed PMID: 7816759. 10: Kudriashov IE. [The potentiating action of vasopressin is not blocked by ketamine]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1994 Jul-Oct;44(4-5):862-4. Russian. PubMed PMID: 7810231. 11: Ebenezer IS. The effects of subcutaneous administration of arginine-8-vasopressin on the electroencephalogram of conscious rats are mediated by peripheral vasopressin V1 receptors. Methods Find Exp Clin Pharmacol. 1994 Jun;16(5):315-21. PubMed PMID: 7934310. 12: Westenberg HG, Hijman R, Wiegant VM, Laczi F, Van Ree JM. Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. Peptides. 1994;15(6):1101-4. PubMed PMID: 7991455. 13: Popik P, Van Ree JM. Social transmission of flavored tea preferences: facilitation by a vasopressin analog and oxytocin. Behav Neural Biol. 1993 Jan;59(1):63-8. PubMed PMID: 8442734. 14: Diamant M, De Wied D. Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats. Am J Physiol. 1993 Jan;264(1 Pt 2):R51-61. PubMed PMID: 8430886. 15: Bohnen NI, Twijnstra A, Jolles J. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. Neurology. 1993 Jan;43(1):103-6. PubMed PMID: 8423870. 16: Zhang WN, Wu FM, Zhang ZX, Xiao XS, Zhang Y, Wang JX, Chen RS. [Effect of DGAVP and Org2766 on intracellular free Ca2+ concentration in dissociated brain cells]. Yao Xue Xue Bao. 1993;28(9):655-60. Chinese. PubMed PMID: 8010010. 17: Kornet M, Goosen C, Thyssen JH, Van Ree JM. Endocrine profile during acquisition of free-choice alcohol drinking in rhesus monkeys; treatment with desglycinamide-(Arg8)-vasopressin. Alcohol Alcohol. 1992 Jul;27(4):403-10. PubMed PMID: 1329787. 18: Lehr CM, Bouwstra JA, Kok W, De Boer AG, Tukker JJ, Verhoef JC, Breimer DD, Junginger HE. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J Pharm Pharmacol. 1992 May;44(5):402-7. PubMed PMID: 1359054. 19: Wan R, Diamant M, de Jong W, de Wied D. Differential effects of ACTH4-10, DG-AVP, and DG-OXT on heart rate and passive avoidance behavior in rats. Physiol Behav. 1992 Mar;51(3):507-13. PubMed PMID: 1326112. 20: Stern GM. New drug interventions in Alzheimer's disease. Curr Opin Neurol Neurosurg. 1992 Feb;5(1):100-3. Review. PubMed PMID: 1623227.